Skip to main content

ECCO 2026

Immunodiagnostics
Molecular diagnostics
Stockholm, Sweden | Europe | Booth #24
Register to event

Join Diasorin at ECCO 2026

February 19 - 21 · Booth #24


Join us in Stockholm for the European Crohn’s and Colitis Organisation Congress. We’re proud to be part of this leading scientific meeting dedicated to advancing care for patients with Inflammatory Bowel Disease (IBD). 

Whether you work in primary or secondary care, conduct research, or support patients’ wellbeing, we’d love to welcome you at booth #24 to explore how Diasorin’s diagnostic solutions help clinicians deliver timely, accurate, and patient-centered care.
 

 INFLAMMATORY BOWEL DISEASE 

The IVDR-compliant LIAISON® Calprotectin assay now includes an indication for monitoring IBD. This update reflects real-world clinical needs: 

  • Beyond differential diagnosis: Fecal calprotectin (FC) is not only a valuable tool for distinguishing active intestinal inflammation from functional disorders such as Irritable Bowel Syndrome (IBS) but also plays a critical role in monitoring disease activity in patients with Crohn’s disease (CD) and ulcerative colitis (UC).
  • Early detection: FC can detect intestinal inflammation before clinical symptoms appear, reducing reliance on invasive endoscopy during routine IBD follow-up.
  • Therapy optimization: FC supports treatment adjustments for long-term disease control.
  • Relapse prediction: FC levels are highly predictive of relapse risk after therapeutic de-escalation. 

These benefits are strongly supported by international clinical guidelines and consensus statements: 

  • ECCO-ESGAR-ESP-IBUS guideline recommends FC testing every 3–6 months alongside systemic markers such as CRP for disease monitoring1.  
  • NICE guideline highlights FC testing for post-diagnosis monitoring to help prioritize colonoscopies and optimize care pathways2.  
  • MSAC and GESA guidelines recognize FC as a valuable tool for tracking disease activity in IBD care3.  
  • STRIDE-II consensus confirms FC’s role in treat-to-target strategies, particularly in UC4.  
  • Evidence from the EuReCa study shows that regular FC testing predicts relapses in quiescent UC, enabling proactive, patient-centered management5. 
COMPREHENSIVE GASTROINTESTINAL DIAGNOSTIC SOLUTIONS 

Diasorin supports every step of the GI diagnostic pathway, from differential diagnosis and infection detection to disease monitoring and pre-therapy screening. Our portfolio includes solutions for: 

  • IBD vs IBS: Calprotectin
  • Monitoring IBD: Calprotectin
  • Pre-therapy screening in IBD: M. tuberculosis, CMV, HBV, HCV
  • Exocrine Pancreatic Insufficiency: Elastase-1
  • Bacterial & Viral Infections: C. difficile GDH, C. difficile Toxins A&B, H. pylori Ag, Campylobacter Ag, Adenovirus, and Rotavirus
  • Celiac Disease: tTG IgA
  • Hepatitis Diagnostic: HAV, HBV, HCV, HDV, HEV 
LIAISON® CALPROTECTIN - HIGHLIGHTED SCIENTIFIC PUBLICATIONS  
  • Campbell, J. et al. 2021. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. DOI:10.1097/MCG.0000000000001359
  • Fiorino, G. et al. 2022. LIAISON® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study. DOI: 10.1002/ueg2.12268
  • Osredkar J. et al. 2021. The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease. DOI: https://doi.org/10.11613/BM.2021.020707
  • Pelkmans, L. et al. 2019. Analytical Performance and Clinicopathologic Correlation of Four Fecal Calprotectin Methods. DOI: 10.1093/AJCP/AQZ051
  • Wyness, S. et al. 2021. Clinical and Analytical Verification of an Automated Fecal Calprotectin Immunoassay with Extraction Device. DOI: 10.1093/jalm/jfaa236
Survey: Understanding Diagnostic Practices in Stool

We invite all congress attendees to participate in our short survey. Your insights will help us better understand current practices, challenges, and needs in gastrointestinal diagnostics. 
Take the survey

Calendar
From 19 February 2026 - 09:00 AM (CET)
To 21 February 2026
Add to Calendar
Add to Calendar 2026-02-19T08:00:00 2026-02-21T17:00:00 ECCO 2026 <h2>Join Diasorin at ECCO 2026</h2><h2>February 19 - 21 · Booth #24</h2><p><br>Join us in Stockholm for the European Crohn’s and Colitis Organisation Congress. We’re proud to be part of this leading scientific meeting dedicated to advancing care for patients with Inflammatory Bowel Disease (IBD).&nbsp;</p><p>Whether you work in primary or secondary care, conduct research, or support patients’ wellbeing, we’d love to welcome you at booth #24 to explore how Diasorin’s diagnostic solutions help clinicians deliver timely, accurate, and patient-centered care.<br>&nbsp;</p><h6>&nbsp;INFLAMMATORY BOWEL DISEASE&nbsp;</h6><p>The IVDR-compliant <strong>LIAISON<sup>®</sup> Calprotectin</strong> assay now includes an indication for <strong>monitoring IBD</strong>. This update reflects real-world clinical needs:&nbsp;</p><ul><li><strong>Beyond differential diagnosis</strong>: Fecal calprotectin (FC) is not only a valuable tool for distinguishing active intestinal inflammation from functional disorders such as Irritable Bowel Syndrome (IBS) but also plays a critical role in monitoring disease activity in patients with Crohn’s disease (CD) and ulcerative colitis (UC).</li><li><strong>Early detection</strong>: FC can detect intestinal inflammation before clinical symptoms appear, reducing reliance on invasive endoscopy during routine IBD follow-up.</li><li><strong>Therapy optimization</strong>: FC supports treatment adjustments for long-term disease control.</li><li><strong>Relapse prediction</strong>: FC levels are highly predictive of relapse risk after therapeutic de-escalation.&nbsp;</li></ul><p>These benefits are strongly supported by international clinical guidelines and consensus statements:&nbsp;</p><ul><li><strong>ECCO-ESGAR-ESP-IBUS guideline</strong> recommends FC testing every 3–6 months alongside systemic markers such as CRP for disease monitoring<sup>1</sup>. &nbsp;</li><li><strong>NICE guideline</strong> highlights FC testing for post-diagnosis monitoring to help prioritize colonoscopies and optimize care pathways<sup>2</sup>. &nbsp;</li><li><strong>MSAC and GESA guidelines</strong> recognize FC as a valuable tool for tracking disease activity in IBD care<sup>3</sup>. &nbsp;</li><li><strong>STRIDE-II consensus</strong> confirms FC’s role in treat-to-target strategies, particularly in UC<sup>4</sup>. &nbsp;</li><li>Evidence from the <strong>EuReCa study</strong> shows that regular FC testing predicts relapses in quiescent UC, enabling proactive, patient-centered management<sup>5</sup>.&nbsp;</li></ul><h6>COMPREHENSIVE GASTROINTESTINAL DIAGNOSTIC SOLUTIONS&nbsp;</h6><p>Diasorin supports every step of the GI diagnostic pathway, from differential diagnosis and infection detection to disease monitoring and pre-therapy screening. Our portfolio includes solutions for:&nbsp;</p><ul><li><strong>IBD vs IBS</strong>: Calprotectin</li><li><strong>Monitoring IBD</strong>: Calprotectin</li><li><strong>Pre-therapy screening in IBD</strong>: <em>M. tuberculosis</em>, CMV, HBV, HCV</li><li><strong>Exocrine Pancreatic Insufficiency</strong>: Elastase-1</li><li><strong>Bacterial &amp; Viral Infections</strong>: <em>C. difficile</em> GDH, <em>C. difficile </em>Toxins A&amp;B, <em>H. pylori </em>Ag, Campylobacter Ag, Adenovirus, and Rotavirus</li><li><strong>Celiac Disease</strong>: tTG IgA</li><li><strong>Hepatitis Diagnostic</strong>: HAV, HBV, HCV, HDV, HEV&nbsp;</li></ul><h6>LIAISON<sup>®</sup> CALPROTECTIN - HIGHLIGHTED SCIENTIFIC PUBLICATIONS &nbsp;</h6><ul><li>Campbell, J. <em>et al.</em> 2021. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. <a href="https://doi.org/10.1097/mcg.0000000000001359" target="_blank" rel="noopener noreferrer">DOI:10.1097/MCG.0000000000001359</a></li><li>Fiorino, G. et al. 2022. LIAISON<sup>®</sup> Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study. <a href="https://doi.org/10.1002/ueg2.12268" target="_blank" rel="noopener noreferrer">DOI: 10.1002/ueg2.12268</a></li><li>Osredkar J. <em>et al.</em> 2021. The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease. <a href="https://doi.org/10.11613/BM.2021.020707" target="_blank" rel="noopener noreferrer">DOI: https://doi.org/10.11613/BM.2021.020707</a></li><li>Pelkmans, L. <em>et al.</em> 2019. Analytical Performance and Clinicopathologic Correlation of Four Fecal Calprotectin Methods. <a href="https://academic.oup.com/ajcp/article/152/3/392/5509899" target="_blank" rel="noopener noreferrer">DOI: 10.1093/AJCP/AQZ051</a></li><li>Wyness, S. et al. 2021. Clinical and Analytical Verification of an Automated Fecal Calprotectin Immunoassay with Extraction Device. <a href="https://academic.oup.com/jalm/article/6/4/931/6134832" target="_blank" rel="noopener noreferrer">DOI: 10.1093/jalm/jfaa236</a></li></ul><h6>Survey: Understanding Diagnostic Practices in Stool</h6><p>We invite all congress attendees to participate in our short survey. Your insights will help us better understand current practices, challenges, and needs in gastrointestinal diagnostics.&nbsp;<br><a href="https://forms.office.com/Pages/ResponsePage.aspx?id=HnNa4sM1xkOQxGa4VubdJdqR2xqrILBLpuh1YO71eBRURjQzRUlMSjM2MVRYTTJaRE9OVE1EN0FVOC4u" target="_blank" rel="noopener noreferrer">Take the survey</a></p> Stockholm, Sweden Diasorin diasorin@nomail.com Europe/Stockholm public
Event will start in
Days
:
Hours
:
Minutes
Share this event

Register now for more information

Complete this form to stay up to date with ECCO 2026

 

REFERENCES:
  1. Kucharzik, T. et al. (2025). ECCO-ESGAR-ESP-IBUS guideline on diagnostics and monitoring of patients with inflammatory bowel disease: Part 1. Journal of Crohn’s and Colitis, 19(7), jjaf106. https://doi.org/10.1093/ecco-jcc/jjaf106  
  2. National Institute for Health and Care Excellence (NICE). (2013, reviewed 2017 – no updates). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11). NICE Diagnostics Guidance. https://www.nice.org.uk/guidance/dg11
  3. Gastroenterological Society of Australia (GESA). (2025, February 6). Faecal calprotectin for the monitoring of disease activity in patients with inflammatory bowel disease [Press release]. https://www.gesa.org.au  
  4. Turner D., et al. International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-1583. https://doi.org/10.1053/j.gastro.2021.01.031  
  5. Fiorino G, et al. LIAISON® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study. United European Gastroenterol J. 2022 Oct;10(8):836-843. https://doi.org/10.1002/ueg2.12268
Share this event